FindTrial
Sign In

Comparison of fractionated frequency-doubled 1064/532 nm picosecond Nd:YAG lasers and nonablative fractional 1540nm Er:glass in the treatment of facial atrophic scar: a randomized, split-face, double-blind controlled trial

Comparison of fractionated frequency-doubled 1064/532 nm picosecond Nd:YAG lasers and nonablative fractional 1540nm Er:glass in the treatment of facial atrophic scar: a randomized, split-face, double-blind controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045982
Enrollment
Unknown
Registered
2021-05-01
Start date
2020-04-01
Completion date
Unknown
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scar

Interventions

Two groups:picosecond laser versus non-ablative fractional laser

Sponsors

Tongji University Affiliated Skin Disease Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Skin type III–IV; 2. With mild to severe atrophic acne scars on the face; 3. Stable condition for > 6 months; 4. Signed informed consent and cooperated with the follow-up.

Exclusion criteria

Exclusion criteria: Patients with pregnancy, lactation, photosensitive skin disease, keloid constitution, sunburn hyperpigmentation, active lesions on facial skin, history of skin tumors, oral administration of retinoic acid drugs within six months, topical use of retinoic acid drugs, or receiving other treatments for acne scars within one year.

Design outcomes

Primary

MeasureTime frame
ECCA score;—

Secondary

MeasureTime frame
(PRIMOS) rapid skin three-dimensional imaging system;The degree of satisfaction;—

Countries

China

Contacts

Public ContactYu Shi

Tongji University Affiliated Skin Disease Hospital

pflw111@126.com+86 13472418639

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026